Literature DB >> 15121316

Immunogenicity of Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E. coli.

Joseli Oliveira-Ferreira1, Esmeralda Vargas-Serrato, John W Barnwell, Alberto Moreno, Mary R Galinski.   

Abstract

Merozoite surface protein-9 of Plasmodium vivax (PvMSP-9) is highly conserved and present in several malaria species. Here, we present the immunogenic properties of two recombinant glutathione S-transferase (GST) fusion proteins comprising the N-terminus (PvMSP-9-Nt) and the second block of tandem repeats (PvMSP-9-RepII) of PvMSP9. These recombinants proteins were used to immunize BALB/c mice. The specificity and subtyping of the antibodies and the cellular immune responses were evaluated by enzyme-linked immunosorbent assay (ELISA) and ELISPOT, respectively, using the recombinant proteins as antigens. Our results demonstrate that both the N-terminal and the tandem repeat regions of MSP9 are immunogenic in mice. The ELISA antibody titers elicited by PvMSP-9-Nt were significantly higher (1:819,200) than the antibody titers elicited by PvMSP-9-RII (1:409,600). Analysis of IgG subclasses showed that both recombinant proteins induce similar antibody patterns where IgG1, IgG2a and IgG2b were most predominant. Moreover, all sera from mice immunized with either PvMSP-9-Nt or PvMSP-9-RII, which were positive by ELISA showed reactivity with P. vivax, P. cynomolgi, P. knowlesi and P. coatneyi schizonts by immunofluorescence assays (IFA). Similar results were observed in western immunoblot analyses using parasite extracts. Furthermore, immunization of mice with the PvMSP-9-Nt upon stimulation with PvMSP-9-Nt secreted IFN-gamma and IL-5. We have also used the two PvMSP-9 recombinant constructs to show that individuals exposed to P. vivax infections in an endemic area of Brazil had IgG antibodies reactive with the recombinant proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15121316     DOI: 10.1016/j.vaccine.2003.07.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Promiscuous T-cell epitopes of Plasmodium merozoite surface protein 9 (PvMSP9) induces IFN-gamma and IL-4 responses in individuals naturally exposed to malaria in the Brazilian Amazon.

Authors:  J C Lima-Junior; D M Banic; T M Tran; V S E Meyer; S G De-Simone; F Santos; L C S Porto; M T Q Marques; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2010-02-26       Impact factor: 3.641

2.  The evolution and diversity of a low complexity vaccine candidate, merozoite surface protein 9 (MSP-9), in Plasmodium vivax and closely related species.

Authors:  Stella M Chenet; M Andreína Pacheco; David J Bacon; William E Collins; John W Barnwell; Ananias A Escalante
Journal:  Infect Genet Evol       Date:  2013-09-14       Impact factor: 3.342

3.  Duffy Blood Group System and the malaria adaptation process in humans.

Authors:  Gledson Barbosa de Carvalho; Glauber Barbosa de Carvalho
Journal:  Rev Bras Hematol Hemoter       Date:  2011

4.  Characterization of a novel gene for strain typing reveals substructuring of Aspergillus fumigatus across North America.

Authors:  S Arunmozhi Balajee; Sun T Tay; Brent A Lasker; Steve F Hurst; Alejandro P Rooney
Journal:  Eukaryot Cell       Date:  2007-06-08

5.  Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals.

Authors:  J C Lima-Junior; T M Tran; E V S Meyer; B Singh; S G De-Simone; F Santos; C T Daniel-Ribeiro; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

6.  Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3α and MSP-9 in individuals from Brazilian endemic area.

Authors:  Josué C Lima-Junior; Rodrigo N Rodrigues-da-Silva; Dalma M Banic; Jianlin Jiang; Balwan Singh; Gustavo M Fabrício-Silva; Luís C S Porto; Esmeralda V S Meyer; Alberto Moreno; Maurício M Rodrigues; John W Barnwell; Mary R Galinski; Joseli de Oliveira-Ferreira
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

7.  Characterizing PvARP, a novel Plasmodium vivax antigen.

Authors:  Darwin A Moreno-Pérez; Ambar Saldarriaga; Manuel A Patarroyo
Journal:  Malar J       Date:  2013-05-20       Impact factor: 2.979

8.  Evaluation of an in silico predicted specific and immunogenic antigen from the OmcB protein for the serodiagnosis of Chlamydia trachomatis infections.

Authors:  Olfa Frikha-Gargouri; Radhouane Gdoura; Abir Znazen; Boutheina Gargouri; Jalel Gargouri; Ahmed Rebai; Adnene Hammami
Journal:  BMC Microbiol       Date:  2008-12-10       Impact factor: 3.605

9.  Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children.

Authors:  Danielle I Stanisic; Sarah Javati; Benson Kiniboro; Enmoore Lin; Jianlin Jiang; Balwan Singh; Esmeralda V S Meyer; Peter Siba; Cristian Koepfli; Ingrid Felger; Mary R Galinski; Ivo Mueller
Journal:  PLoS Negl Trop Dis       Date:  2013-11-14

10.  Using infective mosquitoes to challenge monkeys with Plasmodium knowlesi in malaria vaccine studies.

Authors:  Jittawadee R Murphy; Walter R Weiss; David Fryauff; Megan Dowler; Tatyana Savransky; Cristina Stoyanov; Olga Muratova; Lynn Lambert; Sachy Orr-Gonzalez; Katie Lynn Zeleski; Jessica Hinderer; Michael P Fay; Gyan Joshi; Robert W Gwadz; Thomas L Richie; Eileen Franke Villasante; Jason H Richardson; Patrick E Duffy; Jingyang Chen
Journal:  Malar J       Date:  2014-06-03       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.